Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2019 · 10-K
Revenue$1.24M$1.24M+63.7% vs Q4 2018 Net Income-$4.48M-$4.48MN/M vs Q4 2018 EPS, diluted—
Gross Profitderived$1,118,000+58.4% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income
Operating Cash Flowderived-$5,523,000N/M Free Cash Flowderived-$5,530,000N/M Margins · derivedGross margin90.1%−3.1 pt vs Q4 2018
Operating margin-553.7%+779.6 pt vs Q4 2018
Net margin-361.2%+5569.2 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 12, 2020 · 72 d after period end